New Analysis of 13,560 Patients Demonstrates DecisionDx®-Melanoma Stratifies Risk Across Histological Subtypes; Findings to be Presented at Fall Clinical Dermatology Conference
Seeking Alpha / 1 hour from now 3 Views
Castle is presenting data on DecisionDx®-Melanoma and its pipeline atopic dermatitis (AD) test at the 25th Annual Fall Clinical Dermatology Conference.
Comments